Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo responses and variability in Phase 2 trials but still promoted Phase 3 trial success. Shareholders who bought stock before April 1, 2024, are urged to contact the law firm to protect their rights. This case highlights potential governance issues affecting investor confidence in Vistagen Therapeutics.
Energy Fuels CEO Bhappu sold 14,375 shares of the company to cover tax withholding obligations. This transaction is a routine financial move related to tax compliance and does not indicate a change in company leadership or strategy. Investors should ...
Tsakos Energy Navigation (TEN), a Greek family-led shipping company, sold a Very Large Crude Carrier (VLCC) for $83 million after paying off debt, boosting its financial stability. The company is also diversifying its fleet by acquiring a second LNG ...
Sunrun's stock has fallen 46% over the past year, appearing cheap at about 6 times expected 2026 earnings. However, underlying business trends are weak, with subscriber additions and margins collapsing, and upfront net subscriber margin falling to 3....
Nvidia has invested $3.5 billion in convertible bonds issued by MediaTek as part of a new partnership to integrate Nvidia technology with MediaTek's custom AI chip business. This collaboration aims to expand MediaTek's presence in the data center mar...
Halozyme Therapeutics reported a 48% year-over-year revenue increase in Q2 2026, driven by a 50% rise in royalty revenue and EBITDA margins reaching 68%. The company is transitioning from dependence on a single product, DARZALEX SC, to a broader, hig...
